Introduction
ASRT stock represents the stocks of Assertio Holdings Inc., a pharmaceutical organisation specializing in pain management and neurology remedies. Investors and analysts intently monitor ASRT due to its precise position in the healthcare quarter. This article offers a comprehensive analysis of ASRT stock, exploring the organization’s monetary performance, product portfolio, marketplace position, and future potentialities.
Table of Contents
Company Overview
Assertio Holdings Inc.
Assertio Holdings Inc. Is an industrial pharmaceutical organization based in Lake Forest, Illinois. The agency specializes in growing and advertising revolutionary drug treatments, specially inside the fields of pain control and neurology. Assertio’s product portfolio includes each branded and usual medicinal drugs aimed at improving patients’ fine of life.
Key Products
- INDOCIN: An oral and suppository answer used to deal with moderate to intense rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis.
- Sympazan: A benzodiazepine prescribed for the adjunctive remedy of seizures associated with Lennox Gastaut syndrome in sufferers aged years or older.
- CAMBIA: A non-steroidal anti-inflammatory drug (NSAID) indicated for the extreme treatment of migraine assaults, with or without charisma.
- Zipsor: An NSAID used for the relief of mild to slight ache in adults.
- SPRIX: An NSAID for the fast-term control of mild to moderately severe ache that requires analgesia on the opioid stage.
- Otrexup: A single dose car injector containing methotrexate, used to deal with intense, lively rheumatoid arthritis, lively polyarticular juvenile idiopathic arthritis, and severe psoriasis in adults.
- ROLVENDEN: A long-performing granulocyte colony-stimulating thing indicated to decrease the incidence of contamination because of febrile neutropenia.
Financial Performance
Recent Earnings
In the third region of 2024, Assertio reported sales of $29.2 million, marking an 18.03% 12 months-over-12 months decline. The internet loss for the region turned into $2.92 million, a widespread development from the $279.5 million loss inside the equal area of the preceding 12 months.
Stock Performance
As of April 10, 2025, ASRT stock is buying and selling at $0.5767 in keeping with share, reflecting a 0.09886% increase from the previous close. The day’s buying and selling range has seen a high of $0.5899 and a low of $0.5138.
Assertio Holdings Inc (ASRT)
$0.58
+$0.05(+9.89%)April nine
$0.54+$0.00(+0.17%)After Hours
1D5D1M6MYTD1Y5Ymax
Open0.53
Volume 565.6K
Day Low0.51
Day High0.59
Year Low 0.51
Year High 1.80
Analyst Ratings
Analyst sentiment for ASRT is fine, with 86% of analysts recommending a “Strong Buy” and 14% suggesting a “Hold.” No analysts presently advocate promoting the inventory.
Market Challenges and Opportunities
Competitive Landscape
Assertio faces challenges from universal competition, in particular affecting merchandise like Indocin. The loss of exclusivity for sure medicinal drugs has brought about expanded competition and pricing pressures. However, Assertio’s focus on high-margin products like Sympazan and Otrexup gives possibilities to mitigate those demanding situations.
Strategic Initiatives
To fortify its market position, Assertio is making an investment in revolutionary dosing solutions and increasing payer insurance for its products. These projects aim to enhance patient get admission to and adherence, doubtlessly driving revenue boom inside the coming years.
Summary
ASRT stock gives buyers exposure to a pharmaceutical organisation navigating both demanding situations and possibilities within the healthcare area. While going through competitive pressures, Assertio strategic attention on high-margin merchandise and revolutionary solutions positions it for capacity increase.
Frequently Asked Questions (FAQs)
Q. What is ASRT inventory?
Ans. ASRT stock represents the shares of Assertio Holdings Inc., a pharmaceutical employer specializing in pain control and neurology treatments.
Q. What are Assertio key merchandise?
Ans. Assertio key merchandise include INDOCIN, Sympazan, CAMBIA, Zipsor, SPRIX, Otrexup, and ROLVENDEN.
Q. What is the cutting-edge stock rate of ASRT?
Ans. As of April 10, 2025, ASRT stock is buying and selling at $0.5767 in line with proportion.
Q. How has Assertio completed financially?
Ans. In Q3 2024, Assertio stated sales of $29.2 million and an internet shortage of $2.92 million.
Q. What is the outlook for ASRT inventory?
Ans. Analyst sentiment is effective, with 86% recommending a “Strong Buy” and 14% suggesting a “Hold.”
Q. What challenges does Assertio face?
Ans. Assertio faces challenges from general opposition and pricing pressures however is addressing them through strategic tasks.
Q. What opportunities does Assertio have?
Ans. Assertio recognition on excessive margin products and innovative dosing answers provide boom possibilities.
Disclaimer: The records supplied in this newsletter are for educational functions only and ought to not be construed as economic advice. Investing in shares entails risks, which includes the potential lack of foremost. Readers are advocated to conduct their own research or talk over with a financial consultant before making investment decisions.